Bio-Synthesis Inc. Pioneers the use of Multi Functional Bridged Nucleic Acid for Diagnostic, Clinical, and Therapeutic Applications

As a pioneer in oligonucleotide synthesis, Bio-Synthesis Inc. has been pursuing the development of new oligonucleotide based technologies that can provide compounds which have superior binding affinity and chemical/biological stability. As such, Bio-Synthesis is excited to begin collaborations for commercial applications using Bridged Nucleic Acids (BNA). These RNA analogues can be synthesized and spiked with DNA or RNA in order to modify the formation of nucleic acid helices. BNA is a cutting edge technology which allows clinical diagnostics and therapeutic fields to take advantage of this novel nucleic acid propelling research to new levels.

In 1997, the first generation BNA (2’-O ,4’-C-methylene-bridged nucleic acid, 2’,4’-BNA, also known as LNA) was developed. This was followed by development of second generation BNAs such as 2’,4’-BNA-COC, 5’-amino-2’,4’-BNA. The third generation of 2’,4’-BNA-NC contains a 6-membered ring with a N-O bond between the 2’-hydroxyl and the 4’-carbon of the ribose moiety. It exhibits very strong binding affinity to complementary single stranded RNA, DNA, and double stranded DNA with a highly sequence-selective mode. Most significantly, BNA exhibits a superior binding affinity to complementary RNA. BNA-NC also possesses great stability due to its nuclease resistant properties. For more information on Bridged Nucleic Acids (BNAs) visit our web site.

"In the past two decades we have seen the development of chemically modified oligonucleotides with binding properties which are superior to DNA and RNA,” said Dr. Miguel Castro, CEO of Bio-Synthesis. “Most of these oligonucleotides also have increased affinity to complementary DNA. Some analogs such as Peptide Nucleic Acids (PNA) are fairly stable. However, they also have several disadvantages including a tendency to aggregate, limitation in size due to solubility issues and difficulty in integrating into chimeras of mixed oligos. The first generation BNA (2’,4’-BNA/LNA) has adequate RNA binding affinity and fair stability to exonucleases. Third generation BNA (BNA-NC) improves on that by exhibiting superior binding affinity towards single stranded RNA, a superior binding affinity to double stranded DNA and excellent enzymatic stability to exonucleases, thereby making BNA a great choice for many biological applications.”

Bio-Synthesis is a provider of custom peptide synthesis, antibodies, bioconjugation products, DNA, RNA, BNA, organic synthesis products, gene synthesis, cloning technology, detection kits, cell line authentication, and a diverse number of biomolecular products for the biomedical and life science community worldwide.

"We aim to expand our product offering with oligonucleotides which are sufficiently stable in physiological conditions and bind well to RNA complements. Variation of N-substitution at the 6-membered ring will result in additional advantages for biological applications,” Dr. Castro said. “We are very excited to introduce BNA-NC oligonucleotides to the biomedical research community. These oligonucleotides will have a great impact in antisense, siRNA, SNP detection, FISH as well as a variety of diagnostic applications. BNA-NC is used both as a primer and as a probe in a variety of PCR and RT-PCR applications as well as applications in Molecular Biology research and commercial areas."

For more information, please contact Bio-Synthesis, Inc.

With over 28 years of experience producing custom products for both research and pharmaceutical use, Bio-Synthesis has developed a reputation for both small and large scale synthesis using optimal processes that meet your specifications. BSI is a U.S. based company, therefore all products are exclusively manufactured at the state-of-the-art facilities in Lewisville, Texas.

Bio-Synthesis, Inc.
612 East Main Street
Lewisville, TX 75057

This release was published on openPR.